Storfib 145 mg Tablet (10 Tab)1 / 2

Storfib 145 mg Tablet (10 Tab)

Prescription requiredRx Required

Salt Composition: Atorvastatin (10mg) + Fenofibrate (145mg)

Expiry Date: 01/2028

Special offer

Enquire

Inclusive of all taxes

▼

10 Tab

About The Product

Used to lower high triglycerides and improve heart health

Overview

Storfib 145 tablet is a fixed-dose combination tablet made by Sun Pharma. Each tablet is listed as atorvastatin 10 mg plus fenofibrate 145 mg.

Atorvastatin is a statin that lowers LDL cholesterol. Fenofibrate lowers triglycerides and raises HDL cholesterol.

But it also contains a statin. However, it should only be used when your doctor has weighed it.

Quick Product Facts

Item

Detail

Active ingredients

Atorvastatin 10 mg + fenofibrate 145 mg per tablet

Maker and pack

Sun Pharmaceutical Industries: strip of 10 tablets

Drug classes

Statin (HMG-CoA reductase inhibitor) and fibrate (PPAR alpha agonist)

Usual timing

Both components are once-daily medicines. Swallow the tablet whole.

Storage

Fenofibrate: Store at 25°C and protect from moisture

Prescription status

Prescription medicine.

Uses and Indications

  • Atorvastatin: to lower the risk of heart attack, stroke, and angina in adults with or at risk of heart disease, and to lower LDL cholesterol.

  • Fenofibrate: as an add-on to diet to lower triglycerides in adults with severe hypertriglyceridemia (500 mg/dL or more). Also to lower LDL cholesterol in primary hyperlipidemia when the recommended LDL-lowering treatment cannot be used.

How It Works

Storfib 145 tablet blocks HMG-CoA reductase, the liver enzyme that makes cholesterol, so the liver removes more LDL from the blood. The medicine turns into fenofibric acid, which activates the PPAR alpha receptor.

This speeds the breakdown of triglyceride-rich particles by activating lipoprotein lipase and reducing apoprotein C-III. Fenofibric acid peaks 6 to 8 hours after a dose, reaches steady state within 9 days, and has a half-life of about 20 hours.

Food does not change its exposure. Atorvastatin peaks in 1 to 2 hours, and its effect lasts 20 to 30 hours.

Clinical Evidence

In short, fenofibrate lowers triglycerides well, but it did not reduce heart attacks or deaths, even when added to a statin. Atorvastatin did reduce events.

Study

Setting

Key result

Triglyceride trials (fenofibrate)

147 adults with high triglycerides; 8 weeks

Triglycerides fell 46% (350 to 499 mg/dL) and 54.5% (500 to 1,500 mg/dL). HDL rose 20% to 23%. LDL rose 14.5% and 45%.

Primary hyperlipidemia (fenofibrate)

Four trials, 361 on treatment, 3 to 6 months

LDL fell 20.6%, total cholesterol 18.7%, and triglycerides 28.9%. HDL rose 11%.

ACCORD Lipid

5,518 people with type 2 diabetes on a statin; fenofibrate added; 4.7 years

Major cardiovascular events: hazard ratio 0.92 (0.79 to 1.08). No benefit shown.

FIELD

9,795 people with type 2 diabetes; 5 years

Coronary events: hazard ratio 0.89 (0.75 to 1.05). Total deaths: 1.11 (0.95 to 1.29).

ASCOT-LLA (atorvastatin 10 mg)

10,305 adults with high blood pressure; median 3.3 years

Coronary events fell 36% (1.9% vs 3.0%).

CARDS (atorvastatin 10 mg)

2,838 adults with type 2 diabetes; median 3.9 years

Major events: 83 vs 127 (hazard ratio 0.63).

LDL cholesterol fell 39% on atorvastatin 10 mg in dose-response trials. The key message: this tablet lowers lipid numbers, but the ACCORD result shows that adding fenofibrate to a statin did not lower heart events in people with type 2 diabetes.

Side Effects

In Storfib 145 tablet trials, adverse reactions led to stopping in 5% of patients against 3% on placebo, and raised liver tests were the most frequent cause.

Effect (fenofibrate trials)

Fenofibrate (439)

Placebo (365)

Abnormal liver tests

8%

1%

Abdominal pain

5%

4%

Raised ALT

3%

2%

Raised AST

3%

1%

Raised creatine phosphokinase (CPK)

3%

1%

Constipation

2%

1%

Rhinitis

2%

1%

ALT rose above 3 times normal in 5.3% on fenofibrate, against 1.1% on placebo. For atorvastatin, the most common effects (5% or more) were colds, joint pain, diarrhea, limb pain, and urinary infections. Most were nearly as common on placebo. Urticaria occurred in 1.1% and rash in 1.4% on fenofibrate.

Serious side effects

In short: serious effects are uncommon, but each needs quick action. Learn the warning signs in Section 7.

  • Muscle damage: Myopathy and rhabdomyolysis. The risk rises when a fibrate and a statin are taken together.

  • Liver injury: Serious drug-induced liver injury, including liver transplantation and death, was reported with Storfib 145 tablets within weeks or after months.

  • Allergy and skin: Anaphylaxis and angioedema, and severe skin reactions including Stevens-Johnson syndrome, toxic epidermal necrolysis, and DRESS, days to weeks after starting.

  • Gallstones and pancreatitis: Storfib 145 tablet raises cholesterol in bile. Pancreatitis has been reported.

  • Kidneys: Serum creatinine can rise, usually returning after stopping.

  • Clots: In FIELD, pulmonary embolism occurred in 1.1% on the Storfib 145 tablet against 0.7% on the placebo, and deep vein thrombosis in 1.4% against 1.0%.

  • Blood and HDL: Falls in hemoglobin and white cells, rarely low platelets or agranulocytosis. HDL cholesterol can fall severely in some people.

  • Blood sugar: HbA1c and fasting glucose can rise on statins.

Critical Safety Warning

Seek immediate emergency medical help if you experience:

  • Swelling of the face, lips, or throat, or severe trouble breathing (allergy).

  • A spreading rash, blisters, or peeling skin, with fever or mouth or eye sores (severe skin reaction).

  • Sudden shortness of breath, chest pain, or a swollen, painful leg (possible blood clot).

  • Severe muscle pain or weakness with dark urine, fever, or very little urine (muscle breakdown).

  • Severe, persistent belly pain with vomiting (possible pancreatitis).

Call your doctor the same day for:

  • Unexplained muscle pain, tenderness, or weakness, especially with fever or unusual tiredness.

  • Dark urine, pale stools, yellow eyes or skin, upper right belly pain, itching, nausea, or loss of appetite (liver problems).

  • Upper right belly pain after meals, or nausea and vomiting (possible gallstones).

  • Unusual bleeding or bruising if you take warfarin.

  • Excessive thirst or passing much more urine than usual (high blood sugar).

Do not take this tablet if you have severe kidney impairment or are on dialysis, active liver disease or unexplained persistent liver test abnormalities, acute liver failure or decompensated cirrhosis, or gallbladder disease. Do not take it if you are allergic to atorvastatin, fenofibrate, fenofibric acid, or any ingredient.

Dosage and How To Take It

Item

Fenofibrate

Atorvastatin

Usual dose

145 mg once daily for primary hyperlipidemia; 48 or 145 mg for severe triglycerides

Start 10 or 20 mg once daily; range 10 to 80 mg.

Timing

Any time of day, with or without food. Swallow whole; do not crush, break, or chew.

Any time of day, with or without food

Response check

Triglycerides at 4 to 8 weeks; stop if no adequate response after 2 months

Measure the lipid levels within two to four weeks of initiation of therapy or change in dose.

Mild to moderate kidney disease

Start 48 mg once daily; increase only after evaluating kidney function and triglyceride levels.

No atorvastatin dose change; watch for muscle problems

Severe kidney disease or dialysis

Contraindicated

No dose change; watch for muscle problems

  • A fixed tablet has limits: the Storfib 145 tablet holds fenofibrate 145 mg, so it does not suit people who need the 48 mg start dose for reduced kidney function. It also fixes atorvastatin at 10 mg.

  • Diet: You should follow a lipid-lowering diet before and during treatment.

  • Bile acid resins: Take fenofibrate at least 1 hour before or 4 to 6 hours after a resin such as cholestyramine.

  • Food and drink: Avoid more than 1.2 liters of grapefruit juice a day.

Missed Dose

  • If you miss a dose, do not take an extra one.
  • Resume with your next scheduled dose.
  • Do not take two tablets together.
  • Tell your doctor if you often forget, because both medicines work only while you keep taking them.

Safety Advice

Statin plus fibrate

This pairing raises the risk of muscle damage. Report muscle pain early, and tell YOUR doctor about prescribing a new medicine. While using the Storfib 145 tablet.

Risk factors for muscle problems

Age 65 or over, uncontrolled low thyroid, kidney problems, and interacting medicines.

Gallstones

If gallstones are found, the Storfib 145 tablet should be stopped.

Warfarin

Storfib 145 tablet raises warfarin's effect. The INR must be checked often, and the warfarin dose lowered

Alcohol

Tell your doctor if you drink more than 2 glasses a day, which raises the risk of liver injury.

Pregnancy

Use Storfib 145 tablets in pregnancy only if the benefit justifies the risk.

Breastfeeding

Do not breastfeed during treatment and for 5 days after the last Storfib 145 tablet dose.

Older adults

Kidney function guides the Storfib 145 tablet dose, and muscle risk is higher.

Monitoring During Treatment

Check

Guidance

Why

Liver tests (ALT, AST, bilirubin)

At baseline and periodically, stop if above 3 times normal persistently.

Liver injury

Kidney function

Before starting and periodically, more often if at risk

Creatinine rises, dosing

Triglycerides and LDL

4 to 8 weeks after starting

Response, dose change

Muscle symptoms and CK

Test for unexplained pain, tenderness, or weakness.

Myopathy

Blood counts

Red and white cells during the first 12 months

Blood changes

HDL cholesterol

Within the first few months

Severe HDL fall

INR if on warfarin

Frequently until stable

Bleeding

Blood sugar and HbA1c

Watch in people at risk.

Glucose rise

Fact Box

Item

Detail

Fenofibrate

Prodrug of fenofibric acid; molecular weight 360.83. Half-life is about 20 hours; protein binding is about 99%; about 60% of a dose leaves in urine and 25% in feces.

Atorvastatin

Bioavailability is about 14%; half-life is about 14 hours, activity is 20 to 30 hours; protein binding is 98% or more

Drug-interaction study

Fenofibrate with atorvastatin 20 mg lowered atorvastatin exposure by 17% and did not change fenofibric acid.

Overdose

No specific antidote for either; dialysis is not expected to help

Drug Interactions

Tell your doctor and pharmacist about every medicine and herbal product you take.

  • Fenofibrate, higher muscle risk: statins and colchicine. Doctors weigh the benefit against the risk.

  • Fenofibrate and warfarin: warfarin's effect is stronger. Lower the dose and check INR often.

  • Fenofibrate and kidney: Cyclosporine and tacrolimus can harm the kidneys, and fenofibrate leaves through the kidneys. Use the lowest dose and monitor.

  • Fenofibrate and resins: take 1 hour before or 4 to 6 hours after a bile acid resin.

  • Atorvastatin, not recommended: cyclosporine, gemfibrozil, tipranavir with ritonavir, and glecaprevir with pibrentasvir.

  • Atorvastatin dose caps: 20 mg a day with clarithromycin, itraconazole, and some HIV and hepatitis C medicines. 40 mg with nelfinavir.

  • Atorvastatin, other: Niacin at lipid-lowering doses, and other fibrates raise muscle risk. Take rifampin at the same time. Digoxin and oral contraceptive levels can rise.

FAQs

Storfib 145 tablet combines atorvastatin and fenofibrate to lower cholesterol and triglycerides in one tablet. Doctors prescribe it when both are raised.

It is not a treatment for heart disease on its own, and it does not replace diet and exercise. Your doctor decides whether this combination suits you.

References

  1. Viatris Specialty LLC. LIPITOR (atorvastatin calcium) tablets,revised 4/2024.

  2. AbbVie Inc. TRICOR (fenofibrate) tablets, revised 6/2025 (reproduced by ).

  3. Medindia. Storfib (145+10) tablet listing, 10 tablets.

  4. ACCORD Study Group. Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus. New England Journal of Medicine

  5. Keech A, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus

i
Trust & safety

Medical Disclaimer

Accurate, reviewed information to support informed healthcare decisions

For informational purposes only
Not a substitute for professional medical advice
Consult your doctor for diagnosis and treatment

Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.

The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.

This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.

Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.

Always follow advice from your doctor, pharmacist, or other licensed healthcare professional before starting, stopping, or changing any medicine or treatment.
Magicine PharmacopyCopyright 2026